Butalbital Acetaminophen Capsule
Mayne Pharma Group announces the launch of the butalbital acetaminophen (APAP) capsule 50 mg/300 mg in the United States. This is a new capsule formulation of butalbital/APAP, which is indicated for the treatment of tension headache (migraine). Complementary to Mayne Pharma’s butalbital/APAP tablet 50 mg/300 mg, this capsule formulation provides alternative treatment choices for patients who previously only had a tablet option. The company expects several product launches within the coming year, with 14 drug applications pending US FDA approval.
Mayne Pharma (USA) Inc
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.